Company News
Nektar Therapeutics Shares Surge 20% on Trial Data
Nektar Therapeutics shares jumped about 20% after reporting positive 52‑week Phase 2b data for rezpegaldesleukin in severe alopecia areata.
In the study, 29% (18 µg/kg) and 31% (24 µg/kg) of patients
